FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2342247822> ?p ?o ?g. }

• W2342247822 endingPage "21" @default.
• W2342247822 startingPage "15" @default.
• W2342247822 abstract "Aim: To characterise usage and monitoring of intravenous tobramycin in cystic fibrosis (CF) patients in Australia and the UK. Methods: An anonymous, online survey of healthcare professionals caring for CF patients was conducted. Survey questions were designed to obtain information on tobramycin dosing, therapeutic drug monitoring and toxicity monitoring. Results: The survey was sent to pharmacists and clinicians in 73 CF centres. Responses were received from 32 and 40 healthcare professionals, from Australia and the UK, respectively. Once-daily dosing of tobramycin was the preferred administration regimen for 93.8 and 67.5% of participants in Australia and the UK, respectively. Among them 68.8% of Australian and 55% of UK participants initiated tobramycin therapy at a dose of 10 mg/kg/day or greater. Australian participants most commonly adjusted tobramycin dosage using log-linear regression analysis (40.6%) or trough measurements (28.1%). UK participants most commonly adjusted tobramycin dosage using trough (55%) or peak and trough measurements (37.5%). In 90.6% of Australian and 95% of UK participants practices, serum creatinine was routinely monitored during admission. Standard pure tone audiometry was performed by 15.6% of Australian and 17.5% of UK participants and high-frequency pure tone audiometry was performed by 15.6% of Australian and 10% of UK participants, once or twice a year. Conclusions: Many discrepancies exist between Australia and the UK and within each country with respect to monitoring of intravenous tobramycin in CF patients. Greater ototoxicity monitoring is likely necessary in both countries. Further education of health professionals about the existence of national guidelines and guidance on how they can be applied in practice is likely required." @default.
• W2342247822 created "2016-06-24" @default.
• W2342247822 creator A5046443240 @default.
• W2342247822 creator A5067683450 @default.
• W2342247822 creator A5069997063 @default.
• W2342247822 date "2016-03-01" @default.
• W2342247822 modified "2023-10-14" @default.
• W2342247822 title "Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the UK" @default.
• W2342247822 cites W1561900493 @default.
• W2342247822 cites W1892779545 @default.
• W2342247822 cites W1929477948 @default.
• W2342247822 cites W1965409354 @default.
• W2342247822 cites W1975806439 @default.
• W2342247822 cites W1983222092 @default.
• W2342247822 cites W1992266226 @default.
• W2342247822 cites W2006333306 @default.
• W2342247822 cites W2011719960 @default.
• W2342247822 cites W2030833828 @default.
• W2342247822 cites W2035725634 @default.
• W2342247822 cites W2039121822 @default.
• W2342247822 cites W2039740101 @default.
• W2342247822 cites W2067033652 @default.
• W2342247822 cites W2098645786 @default.
• W2342247822 cites W2132491970 @default.
• W2342247822 cites W2139226586 @default.
• W2342247822 cites W2155032379 @default.
• W2342247822 cites W2155681864 @default.
• W2342247822 cites W2156731012 @default.
• W2342247822 doi "https://doi.org/10.1002/jppr.1145" @default.
• W2342247822 hasPublicationYear "2016" @default.
• W2342247822 type Work @default.
• W2342247822 sameAs 2342247822 @default.
• W2342247822 citedByCount "15" @default.
• W2342247822 countsByYear W23422478222016 @default.
• W2342247822 countsByYear W23422478222017 @default.
• W2342247822 countsByYear W23422478222018 @default.
• W2342247822 countsByYear W23422478222019 @default.
• W2342247822 countsByYear W23422478222021 @default.
• W2342247822 countsByYear W23422478222022 @default.
• W2342247822 crossrefType "journal-article" @default.
• W2342247822 hasAuthorship W2342247822A5046443240 @default.
• W2342247822 hasAuthorship W2342247822A5067683450 @default.
• W2342247822 hasAuthorship W2342247822A5069997063 @default.
• W2342247822 hasConcept C126322002 @default.
• W2342247822 hasConcept C177713679 @default.
• W2342247822 hasConcept C2775832221 @default.
• W2342247822 hasConcept C2776938444 @default.
• W2342247822 hasConcept C2778974779 @default.
• W2342247822 hasConcept C3020230634 @default.
• W2342247822 hasConcept C501593827 @default.
• W2342247822 hasConcept C71924100 @default.
• W2342247822 hasConcept C86803240 @default.
• W2342247822 hasConcept C89423630 @default.
• W2342247822 hasConceptScore W2342247822C126322002 @default.
• W2342247822 hasConceptScore W2342247822C177713679 @default.
• W2342247822 hasConceptScore W2342247822C2775832221 @default.
• W2342247822 hasConceptScore W2342247822C2776938444 @default.
• W2342247822 hasConceptScore W2342247822C2778974779 @default.
• W2342247822 hasConceptScore W2342247822C3020230634 @default.
• W2342247822 hasConceptScore W2342247822C501593827 @default.
• W2342247822 hasConceptScore W2342247822C71924100 @default.
• W2342247822 hasConceptScore W2342247822C86803240 @default.
• W2342247822 hasConceptScore W2342247822C89423630 @default.
• W2342247822 hasIssue "1" @default.
• W2342247822 hasLocation W23422478221 @default.
• W2342247822 hasOpenAccess W2342247822 @default.
• W2342247822 hasPrimaryLocation W23422478221 @default.
• W2342247822 hasRelatedWork W1983518146 @default.
• W2342247822 hasRelatedWork W1999595197 @default.
• W2342247822 hasRelatedWork W2045568616 @default.
• W2342247822 hasRelatedWork W2077044820 @default.
• W2342247822 hasRelatedWork W2123413550 @default.
• W2342247822 hasRelatedWork W2790721707 @default.
• W2342247822 hasRelatedWork W2947032946 @default.
• W2342247822 hasRelatedWork W2947380944 @default.
• W2342247822 hasRelatedWork W3034070945 @default.
• W2342247822 hasRelatedWork W4256186082 @default.
• W2342247822 hasVolume "46" @default.
• W2342247822 isParatext "false" @default.
• W2342247822 isRetracted "false" @default.
• W2342247822 magId "2342247822" @default.
• W2342247822 workType "article" @default.